November/December 2016

For this issue, we gave cardiologists a crystal ball, figuratively, of course, and asked them what they saw for their specialty’s future.

Performance-based risk-sharing deals allow payers to hedge their bets with new drugs while helping pharmaceutical companies grow market share.

Transcatheter aortic valve replacement offers valuable lessons that can be applied to its mitral valve counterpart, according to imagers on the frontlines for both techniques.

What trends will have the greatest impact on interventional cardiology, and which tools will evolve to help the field manage transformation?

Topping the list of must haves when rolling out a new complex PCI program are a solid mission to offer leading-edge technology, top-down administrative support, physician and nursing leadership, a quest for quality, and a well-oiled team.

Cardiologists are leveraging telemedicine to be in two places at once.

A new AHA statement examines the potential of wearable cardioverter-defibrillators to protect against cardiac arrest.

SCAI examines the implications of the FDA’s decision to expand the TAVR indication to include patients at intermediate risk for SAVR.

More patients with complex diseases, added pressure to take care of them after discharge and greater expectations to demonstrate quality of care. Together, these cardiovascular service line (CVSL) realities translate into much more data to manage, and the need for someone to do it.